Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

U Blank

Showing results (191-200 of 317) with videos related to

Pageof 32
Sort By:
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Journal for Immunotherapy of Cancer|December 2, 2020
Comprehensive analysis of cutaneous and uveal melanoma liver metastasesEsmee P Hoefsmit, Elisa A Rozeman, Trieu My Van, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Scandinavian Journal of Immunology|March 31, 2016
Identification of Biological and Pharmaceutical Mast Cell- and Basophil-Related TargetsO Klein, F Ngo-Nyekel, T Stefanache, et al.
Annals of Surgical Oncology|January 23, 2026
ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated MelanomaAlaa Embaby, Sanne C F A Huijberts, Liqin Wang, et al.
Acta Oncologica (Stockholm, Sweden)|September 14, 2020
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controlsA H Boekhout, A Rogiers, K Jozwiak, et al.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Pageof 32

Showing results (191-200 of 317) with videos related to

Sort By:
Pageof 32
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 11, 2020
Management of early melanoma recurrence despite adjuvant anti-PD-1 antibody therapy<sup>☆</sup>C N Owen, A N Shoushtari, D Chauhan, et al.
Journal for Immunotherapy of Cancer|December 2, 2020
Comprehensive analysis of cutaneous and uveal melanoma liver metastasesEsmee P Hoefsmit, Elisa A Rozeman, Trieu My Van, et al.
Annals of Surgical Oncology|October 14, 2025
International Survey on Evidence for Index Lymph Node Surgery After Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Scandinavian Journal of Immunology|March 31, 2016
Identification of Biological and Pharmaceutical Mast Cell- and Basophil-Related TargetsO Klein, F Ngo-Nyekel, T Stefanache, et al.
Annals of Surgical Oncology|January 23, 2026
ASO Visual Abstract: International Survey on Evidence for Index Lymph Node Surgery Following Neoadjuvant Systemic Therapy for Stage III MelanomaElan Novis, Mervi Rautalin, Rodabe N Amaria, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 13, 2024
A Proof-of-Concept Study of Sequential Treatment with the HDAC Inhibitor Vorinostat following BRAF and MEK Inhibitors in BRAFV600-Mutated MelanomaAlaa Embaby, Sanne C F A Huijberts, Liqin Wang, et al.
Acta Oncologica (Stockholm, Sweden)|September 14, 2020
Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controlsA H Boekhout, A Rogiers, K Jozwiak, et al.
JAMA Surgery|February 9, 2022
Representativeness of the Index Lymph Node for Total Nodal Basin in Pathologic Response Assessment After Neoadjuvant Checkpoint Inhibitor Therapy in Patients With Stage III MelanomaIrene L M Reijers, Robert V Rawson, Andrew J Colebatch, et al.
Cancer Immunology, Immunotherapy : CII|March 11, 2014
Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaSander Kelderman, Bianca Heemskerk, Harm van Tinteren, et al.
European Journal of Cancer (Oxford, England : 1990)|November 21, 2023
The features and management of acquired resistance to PD1-based therapy in metastatic melanomaAdriana Hepner, Judith M Versluis, Roslyn Wallace, et al.
Pageof 32